Investment analysts at Evercore ISI initiated coverage on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research report issued on Wednesday, MarketBeat Ratings reports. The firm set an “in-line” rating and a $137.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price target points to a potential upside of 0.33% from the stock’s current price.

Several other analysts have also commented on ALXN. UBS AG reaffirmed a “buy” rating and set a $140.00 price target (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. BidaskClub lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $120.00 price target on shares of Alexion Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, June 8th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 14th. Five research analysts have rated the stock with a hold rating, twenty have issued a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $156.13.

Alexion Pharmaceuticals (ALXN) traded down 0.3606% on Wednesday, hitting $136.0576. The stock had a trading volume of 165,163 shares. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $145.42. The stock has a market cap of $30.37 billion, a PE ratio of 59.0016 and a beta of 1.41. The firm’s 50 day moving average price is $130.29 and its 200-day moving average price is $123.01.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.13 EPS. On average, analysts forecast that Alexion Pharmaceuticals will post $5.60 EPS for the current year.

WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Now Covered by Analysts at Evercore ISI” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/alexion-pharmaceuticals-inc-alxn-now-covered-by-analysts-at-evercore-isi.html.

In other news, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 2,019,734 shares of company stock valued at $235,606,846. Corporate insiders own 4.35% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. DnB Asset Management AS boosted its stake in Alexion Pharmaceuticals by 9.9% in the first quarter. DnB Asset Management AS now owns 23,408 shares of the biopharmaceutical company’s stock valued at $2,838,000 after buying an additional 2,100 shares during the period. Bank of The West boosted its stake in shares of Alexion Pharmaceuticals by 9.1% in the first quarter. Bank of The West now owns 47,077 shares of the biopharmaceutical company’s stock worth $5,707,000 after buying an additional 3,909 shares during the period. Boston Advisors LLC boosted its stake in shares of Alexion Pharmaceuticals by 28.6% in the first quarter. Boston Advisors LLC now owns 154,396 shares of the biopharmaceutical company’s stock worth $18,719,000 after buying an additional 34,315 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Alexion Pharmaceuticals by 40.7% in the first quarter. Nisa Investment Advisors LLC now owns 54,205 shares of the biopharmaceutical company’s stock worth $6,572,000 after buying an additional 15,670 shares during the period. Finally, Columbus Circle Investors boosted its stake in shares of Alexion Pharmaceuticals by 21.1% in the first quarter. Columbus Circle Investors now owns 75,796 shares of the biopharmaceutical company’s stock worth $9,190,000 after buying an additional 13,183 shares during the period. 90.74% of the stock is owned by institutional investors and hedge funds.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.